Full story: https://grafa.com/en/news/australia/caprice-resources-begins-regional-drilling-and-expands-gold-zones Caprice Resources started a regional aircore drilling programme and reported new drill results that extended gold zones. The company's stock fell 2.86% to $0.068 following the announcement. The drilling aims to test the Break of Day trend and identify new mineralised zones for follow-up reverse circulation drilling. Caprice Resources (ASX:CRS) commenced regional aircore discovery drilling across the western half of the Island Project while returning new drill results that extended gold mineralisation. The fresh exploration push follows prior drilling success at the site, which previously yielded high-grade gold intersections down plunge at the Baxter target. "Aircore drilling i

Full story: https://grafa.com/en/news/australia/australian-ethical-funds-under-management-dip-to-14-43b Australian Ethical total FUM slipped to $14.43 billion as wholesale redemptions offset positive superannuation net flows. The company's share price traded up at $4.18 following the announcement. Management continues expanding its middle-market offering to drive long-term value for customers and shareholders. Australian Ethical Investment (ASX:AEF) reported funds under management of $14.43 billion for the quarter ended Sept. 30, down slightly from $14.50 billion at the end of FY26. The slight decline came as wholesale redemptions and market conditions offset $0.13 billion in positive superannuation net flows. "The first quarter demonstrated the continued momentum and resilience of our bus

Full story: https://grafa.com/en/news/australia/austco-healthcare-to-acquire-caretech-for-4m Austco Healthcare agrees to acquire 100% of CareTech Systems for up to $4 million. The transaction includes an upfront cash payment of $3 million funded through cash reserves and a new debt facility. CareTech brings a portfolio of lower-cost aged care systems and wireless products across roughly 200 sites. Austco Healthcare (ASX:AHC) has entered into a binding agreement to acquire 100% of Brisbane-based CareTech Systems for an estimated total consideration of $4 million. The purchase expands the company's nurse call portfolio with lower-cost aged care and wireless systems currently installed across approximately 200 sites. The acquisition delivers owned products and intellectual property rather tha

Full story: https://grafa.com/en/news/australia/mayne-pharma-resolves-imvexxy-patent-dispute-with-teva Mayne Pharma settled its US Paragraph IV patent litigation with Teva Pharmaceuticals USA concerning IMVEXXY. The resolution involved no upfront monetary payments or cash transfers between either company. Teva agreed to a potential market entry date for generic IMVEXXY on Sept. 2, 2032. Mayne Pharma (ASX:MYX) has settled its US patent litigation with Teva Pharmaceuticals USA over generic versions of the menopause treatment IMVEXXY. The agreement resolves ongoing litigation started in April 2020 and establishes a potential generic product entry date of Sept. 2, 2032. "Following our settlement with Sun Pharma announced on Sept. 30, today’s agreement with Teva Pharmaceuticals USA resolves all

Full story: https://grafa.com/en/news/australia/australia-to-hit-chinese-aluminium-with-70-tariffs The Trade Remedies Commission proposed tariffs of up to 70.4% on Chinese aluminium windows and doors following dumping findings. The investigation revealed local producers suffered $350 million in price undercut losses and $72.6 million in lost sales. The Australian government aims to protect domestic manufacturers from subsidised foreign competition distorting the $2.8 billion market. The Australian Trade Remedies Commission has recommended preliminary tariffs of up to 70.4% on Chinese aluminium window and door imports after finding dumped products caused material injury to local producers. Chinese exporters captured a 19% share of Australia's $2.8 billion annual aluminium window and door ma

Full story: https://grafa.com/en/news/australia/dimerix-completes-first-100-patients-in-action3-phase-3-trial Dimerix announced that the first 100 patients completed the two-year double-blind treatment phase in its global ACTION3 trial. The Dimerix share price fell 4.3% to $0.21 following the market announcement. Completing treatment for 100 patients helps reduce trial execution risk for the company's leading kidney treatment candidate. Dimerix (ASX:DXB) reached a clinical milestone after the first 100 patients finished two years of double-blind treatment in its global ACTION3 Phase 3 trial. This progress provides clinical data continuity after the study previously passed a formal analysis for futility. "The completion of the first 100 patients represents another important milestone for th

Full story: https://grafa.com/en/news/australia/coventry-group-delivers-5-4m-quarterly-ebitda Coventry Group's unaudited earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose 87% year-on-year to $5.4 million. Group sales increased 1.3% compared to the prior corresponding period to reach $100.1 million. Management attributed the earnings surge to lower operating costs and a 50 basis point margin expansion. Coventry Group (ASX:CYG) reported unaudited Q1 FY27 sales of $100.1 million and a pre-AASB16 EBITDA of $5.4 million. Operating expenses fell by $1.5 million, 3.9% lower than the prior corresponding period despite continued inflationary pressure on wages, rents and other costs. Within business divisions, trade distribution sales grew 6.9% to $62.5 million, while flu

Full story: https://grafa.com/en/news/australia/australia-unemployment-rate-rises-to-4-7-in-september The seasonally adjusted unemployment rate rose to 4.7% in September. Total employment fell by 39,000 people as part-time work declined. The Australian Bureau of Statistics noted a higher proportion of people remained unemployed compared to recent years. Australia’s seasonally adjusted unemployment rate reached 4.7% in September as the economy shed 39,000 jobs, according to the Australian Bureau of Statistics. The decline follows a drop in the employment-to-population ratio, which fell 0.3 percentage points to 63.6% after last month showed more people entering the workforce without finding jobs. "This month there were 39,000 less employed people and 9,000 more unemployed people," said ABS H

Full story: https://grafa.com/en/news/australia/firebrick-pharma-secures-philippines-approval-for-nasal-spray Firebrick Pharma has received approval from the Philippines Food and Drug Administration to market Nasodine Nasal Spray as an over-the-counter antiseptic drug. Following the regulatory update, the Firebrick Pharma share price was unchanged at $0.031. The company is partnering with SV More Corporation to prepare for the commercial product launch in the Philippines, targeted for early 2027. Firebrick Pharma (ASX:FRE) has secured marketing authorisation from the Philippines Food and Drug Administration for its Nasodine Nasal Spray as an over-the-counter antiseptic drug. This regulatory approval provides an immediate market pathway into Southeast Asia’s second-largest country, which ha

Full story: https://grafa.com/en/news/australia/helloworld-travel-expects-up-to-84m-earnings Helloworld Travel projects full-year underlying EBITDA to reach $78 million to $84 million for FY27. The guidance includes a planned $14 million contribution from the upcoming Crown Currency Exchange acquisition set for Oct. 30. Strong international travel demand and early forward bookings are driving a projected total transaction value of approximately $4.8 billion. Helloworld Travel (ASX:HLO) announced full-year FY27 guidance, expecting total transaction value to reach approximately $4.8 billion with underlying EBITDA of $78 million to $84 million. First-quarter total transaction value and underlying EBITDA matched prior corresponding period levels despite higher aviation fuel costs and ongoing c

Full story: https://grafa.com/en/news/australia/bcal-diagnostics-introduces-multi-cancer-test-in-sydney-melbourne BCAL Diagnostics introduced the Avantect blood-based test in Australia to screen for eight cancer types. The company's stock remained unchanged following the product rollout announcement. The commercialisation strategy targets national expansion following initial rollouts in Sydney and Melbourne. BCAL Diagnostics (ASX:BDX) has commenced the Australian rollout of the Avantect Multi-Cancer blood-based diagnostic test in Sydney and Melbourne. The phased launch provides local patients access to non-invasive testing capable of detecting signals across eight distinct cancer types alongside organ-of-origin indicators. BCAL CEO Anne-Louise Arnett said, “The direction of cancer diagnost

Full story: https://grafa.com/en/news/australia/aurum-resources-raises-52-5m-for-project Aurum Resources secured $52.5 million in firm commitments through a single-tranche institutional placement to fund its Boundiali Project. The placement was completed at an issue price of $0.55 per share, bringing the company’s expected total cash balance to $95 million. Capital raised will accelerate early development, site access construction, land acquisition, and ongoing exploration drilling. Aurum Resources (ASX:AUE) has secured $52.5 million in firm commitments via a single-tranche institutional placement of roughly 95.5 million new shares to fund development at its Boundiali Gold Project. The issue price of $0.55 per share represents a single-tranche structure, with existing and new strategic inv

Full story: https://grafa.com/en/news/australia/qmines-intersects-broad-copper-zone-in-queensland QMines reported broad copper mineralisation at its Mt Chalmers Project. The announcement supported a 3.13% rise in the company's share price. Assays are pending for 19 holes as part of a 10,000m drilling campaign. QMines (ASX:QML) has intersected a 44m zone of copper mineralisation at its Mt Chalmers open pit in Queensland. The drill results build on the company's continuous exploration efforts aimed at expanding its regional resource footprint. QMines Exploration Manager, Tom Bartschi, said, “The 44m intersection in 26MCRD005 is a strong result, particularly the higher-grade copper intervals within it, while 26MCDD011 is also encouraging given the hole ended in mineralisation and remains unte

Full story: https://grafa.com/en/news/australia/strike-energy-selects-preferred-west-erregulla-processing-pathway Strike Energy established a processing agreement with Hancock Energy for the West Erregulla Gas Project. The transaction secures a target processing capacity net to Strike of 43.5 terajoules per day. The agreement establishes Hancock Energy’s Belisama gas processing facility as the preferred development pathway. Strike Energy (ASX:STX) has chosen Hancock Energy's Belisama Gas Processing Facility as its preferred processing pathway for the West Erregulla Project. The selection provides a clear operational framework compared to earlier standalone processing concepts considered by the joint venture. The agreement targets a processing capacity net to Strike of 43.5 terajoules per d

Full story: https://grafa.com/en/news/australia/dimerix-draws-down-17m-funding-facility Dimerix has drawn down $17 million under its non-dilutive debt facility. The funding extends the company's financial runway without diluting existing shareholder equity. Capital will directly support key clinical programmes, including the ACTION3 Phase 3 trial. Dimerix (ASX:DXB) has drawn down $17 million under a non-dilutive debt facility to fund its key clinical pipeline. The drawdown represents 50% of the overall $34 million facility that the business secured from Australian and United States lenders. "The receipt of these funds further strengthens Dimerix's financial position and supports the continued execution of our key value-driving programmes, including the ACTION3 Phase 3 study of DMX-200 and

Full story: https://grafa.com/en/news/australia/myer-posts-276-5m-loss-as-impairments-hit Myer Holdings reported a full-year statutory loss of $276.5 million. Sales grew to $4.1 billion, but the stock fell after missing profit expectations. Management points to consumer weakness and high cost-of-living pressures as key drivers. Department store retailer Myer (ASX:MYR) reported a full-year statutory loss of $276.5 million after taking a major non-cash impairment charge. The result marked a significant downturn compared to the $211 million loss recorded in the prior financial year. "Consistent with the trends we observed in June and July, trading through the early part of FY27 has remained uneven, with softer conditions experienced in August followed by improving trading momentum through Sep

Full story: https://grafa.com/en/news/australia/australian-gold-and-copper-intersects-zinc-gold-deposit Australian Gold and Copper has confirmed broad zinc-rich mineralisation with consistent gold across multiple drill holes at the Northern Evergreen prospect. The news follows a 21-hole reverse circulation drilling programme testing shallow extensions of drill hole 26DDBR017. Australian Gold and Copper stated the ongoing programme aims to expand its mineral footprint across the South Cobar Basin. Australian Gold and Copper (ASX:AGC) has intersected broad zinc-rich mineralisation carrying consistent gold grades across multiple drill holes at its Northern Evergreen deposit. The discovery follows earlier step-out drilling at the site, which had previously returned shallow high-grade intercept

Full story: https://grafa.com/en/news/australia/nufarm-targets-380m-earnings-for-fy26 Nufarm projects FY26 underlying EBITDA between $370 million and $380 million, representing 25% growth at the midpoint. Leverage is expected to fall from 2.7 times to 2.0 times by September. The company is executing factory closures and product rationalisation to secure $50 million in run-rate cost savings by the end of FY27. Agricultural chemical company Nufarm (ASX:NUF) expects its FY26 underlying EBITDA to reach between $370 million and $380 million. The projected earnings represent an approximate 25% increase compared to the prior corresponding period, driven by growth in hybrid seeds and Omega-3 platforms. Secondary operational details include plans to shut down its manufacturing facility in Alsip in

Full story: https://grafa.com/en/news/australia/tuas-full-year-net-profit-jumps-to-28-7m Tuas recorded a full-year net profit after tax of S$26 million, up from S$6.9 million last year. The company's mobile subscriber base expanded to 1.5 million, driving annual revenue up to S$187.6 million. Tuas acknowledged the intermittent use of unauthorised spectrum while setting aside up to $30 million for cybersecurity. Tuas (ASX:TUA) reported a statutory net profit after tax of S$26 million for the year ended July 31, driven by strong subscriber growth across its mobile and broadband segments. The underlying financial expansion represented a substantial jump from the preceding year when the telecommunications company generated S$6.9 million in net profit on S$151.3 million in revenue. "Simba has b

Full story: https://grafa.com/en/news/australia/iag-to-seek-public-benefits-approval-for-rac-alliance Insurance Australia Group will apply for public benefits approval following an Australian Competition and Consumer Commission merger determination. The ACCC determined in Phase 2 that the proposed alliance with the Royal Automobile Club of Western Australia should not proceed on competition grounds. IAG will pursue a public benefits determination over approximately 50 business days to secure regulatory clearance for the partnership. Insurance Australia Group (ASX:IAG) announced it will make a public benefits application to progress its proposed alliance with the Royal Automobile Club of Western Australia after the Australian Competition and Consumer Commission issued a Phase 2 determinatio